clinical trial · NCT02152631
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Eli Lilly and Company·phase3·active not recruiting·n = 453
Non Small Cell Lung CancerAbemaciclibErlotinib
brief summary
The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.
started
Oct 3, 2014
primary completion
Sep 15, 2017
completion
Dec 1, 2026
last updated
Feb 6, 2026
official title
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol